Balance and management of CRS and infection following CD19-targeted CAR T-cell therapy in primary refractory high-grade B-cell lymphoma: a case report
BackgroundCD19-targeted chimeric antigen receptor T (CAR T) cell therapy has revolutionized the treatment of refractory/relapsed B-cell malignancies. However, this therapy introduces significant safety concerns, including cytokine release syndrome (CRS) and infections, both of which can lead to life...
Saved in:
Main Authors: | Nannan Lu, Yajing Zhang, Chunmeng Wang, Qingming Yang, Guanghua Rong, Yang Liu, Weidong Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Hematology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1616504/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01) -
Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma
by: Zhongqing Zou, et al.
Published: (2025-07-01) -
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01) -
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
by: Yunjia Xian, et al.
Published: (2025-06-01) -
Enhancing CAR T‐cell therapy manufacturing efficiency through semi‐automated bioprocessing
by: Jason Isaacson, et al.
Published: (2025-01-01)